Red Leaf Medical has filed a new drug submission with Health Canada for approval of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections(rUTIs) in women. The new drug submission is supported by results from a UROMUNE™ multicenter, prospective, randomized, double-blind, placebo-controlled trial. These results were recently published in the New England Journal of Medicine Evidence.
Red Leaf Medical is pleased to announce that results from a multicenter randomized placebo-controlled trial of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections in women, were published online in the New England Journal of Medicine Evidence. Data indicates that the new vaccine significantly decreases urinary tract infections and prevents recurrence in women.
Red Leaf Medical is pleased to announce the launch of a new on-demand translation service available in more than 150 languages to meet the diverse needs of its CathetersPLUS™ customers. The company also introduced new educational tools for nurses following research in support of its CathetersPLUS™ mission to improve the lives of patients who use catheters.
Through an exclusive licensing agreement, RLM is preparing to bring new vaccines to Canada to prevent recurrent urinary tract infections and recurrent respiratory tract infections. The agreement includes BACTEK™ and UROMUNE™, novel sublingual vaccines.